Wire · opportunities
Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics' NTS231 ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 September 2026 · Fusion42 review
Nutshell Therapeutics received FDA IND clearance for NTS231, a novel NRF2 degrader molecule discovered through their AI-driven platform, marking the second such drug globally to enter clinical trials. NTS231 targets cancers with NRF2 pathway activation, showing promising preclinical antitumor efficacy and a favourable safety profile.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 25 Sep 2026 and 29 Sep 2026.
◆ ◆ The Wire takeaway
You can now access a new route to treat NRF2-driven cancers previously resistant to therapy, shifting competitive advantage to those integrating AI in drug discovery. This clearance signals an opening in oncology targeting molecular glue degraders that few players have explored.
◆ Coverage
2 sources · first reported 25 Sep 2026 · latest 29 Sep 2026
◆ Related on Wire
◆ Topics